- Home
- PROK vs STRO Comparison
PROK vs STRO Comparison
Compare PROK & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- STRO
- Stock Information
- Founded
- PROK 2015
- STRO 2003
- Country
- PROK United States
- STRO United States
- Employees
- PROK N/A
- STRO N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PROK Health Care
- STRO Health Care
- Exchange
- PROK Nasdaq
- STRO Nasdaq
- Market Cap
- PROK 85.5M
- STRO 77.7M
- IPO Year
- PROK N/A
- STRO 2018
- Fundamental
- Price
- PROK $0.58
- STRO $0.68
- Analyst Decision
- PROK Hold
- STRO Hold
- Analyst Count
- PROK 3
- STRO 7
- Target Price
- PROK $3.50
- STRO $3.97
- AVG Volume (30 Days)
- PROK 1.6M
- STRO 1.4M
- Earning Date
- PROK 08-08-2025
- STRO 08-12-2025
- Dividend Yield
- PROK N/A
- STRO N/A
- EPS Growth
- PROK N/A
- STRO N/A
- EPS
- PROK N/A
- STRO N/A
- Revenue
- PROK $306,000.00
- STRO $66,434,000.00
- Revenue This Year
- PROK $54.34
- STRO N/A
- Revenue Next Year
- PROK N/A
- STRO N/A
- P/E Ratio
- PROK N/A
- STRO N/A
- Revenue Growth
- PROK N/A
- STRO N/A
- 52 Week Low
- PROK $0.46
- STRO $0.52
- 52 Week High
- PROK $2.59
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- PROK 39.26
- STRO 36.17
- Support Level
- PROK $0.54
- STRO $0.76
- Resistance Level
- PROK $0.90
- STRO $0.87
- Average True Range (ATR)
- PROK 0.13
- STRO 0.07
- MACD
- PROK -0.02
- STRO -0.01
- Stochastic Oscillator
- PROK 9.55
- STRO 3.46
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.